Relapsed multiple myeloma requires specialized expertise that goes beyond general oncology pathways. When disease returns after initial treatment, accessing centers with thorough clinical trial portfolios and novel therapy options becomes critical for optimal outcomes. Key Takeaways Second opinions add value when they unlock clinical trial eligibility, access to CAR-T therapy or bispecific antibodies, or materially different treatment sequencing based on your prior therapy li